Investigators presented the first results from a phase I trial testing the concomitant use of tadalafil and injection of autologous pulsed DCs with the Mucin-1 (MUC1) peptide in patients with surgically eligible, recurrent or second primary HNSCC [97]. Here, MUC1 is linked to head and neck squamous cell carcinoma.